Last updated: February 25, 2026
What is the drug associated with NDC 70710-1111?
NDC 70710-1111 is identified as Eptinezumab (Vyepti), a monoclonal antibody developed by Lundbeck for the preventive treatment of migraine in adults. It is administered via intravenous infusion every three months.
Current Market Landscape
FDA Approval and Indications
Eptinezumab received FDA approval in February 2020 for migraine prevention in adults. Its approval opened a pathway into a growing migraine prophylaxis market.
Competition Landscape
Key competitors include:
- Erenumab (Aimovig) by Amgen
- Fremanezumab (Ajovy) by Teva
- Galcanezumab (Emgality) by Lilly
All target CGRP pathways with subcutaneous injections. Eptinezumab's intravenous administration provides a differentiation point.
Market Size and Growth
- The global migraine therapeutics market was valued at approximately $3.6 billion in 2021.
- Compound annual growth rate (CAGR) from 2022 to 2027 is forecasted at 6%.
- North America dominates with over 50% market share[1].
Adoption Rates and Prescribing Trends
- Initial uptake focused on neurologists, with expanding use as insurance coverage stabilizes.
- The convenience of infusions every 3 months improves patient adherence relative to weekly or monthly injections.
- Injection site preferences and patient preferences favor the subcutaneous route but infusion options hold appeal for specific patient groups.
Pricing Dynamics
Current Pricing Data
- The wholesale acquisition cost (WAC) for Eptinezumab is approximately $800 - $850 per infusion.
- The average patient receives 4 infusions annually, totaling roughly $3,200 - $3,400 per year.
Price Comparison with Competitors
| Medication |
Route |
Cost per Dose |
Doses per Year |
Total Annual Cost |
| Eptinezumab (Vyepti) |
IV |
$850 |
4 |
$3,400 |
| Erenumab (Aimovig) |
SC |
$575 |
12 |
$6,900 |
| Fremanezumab (Ajovy) |
SC |
$575 |
12 |
$6,900 |
| Galcanezumab (Emgality) |
SC |
$600 |
12 |
$7,200 |
Eptinezumab's per-infusion cost is higher, but the quarterly schedule may reduce administration costs and improve compliance.
Price Projections
Short-term (Next 1-2 Years)
- Stable pricing expected, with minor fluctuations driven by reimbursement negotiations.
- Insurance coverage expansion may stabilize net prices for providers and patients.
Mid-term (3-5 Years)
- Price competition may pressure net costs downward as more CGRP inhibitors come to market.
- Possible discounts and value-based arrangements may lower effective patient costs by 10-15%.
Long-term (Beyond 5 Years)
- Market penetration into broader patient populations may lead to volume-based discounts.
- Emergence of biosimilars is unlikely within this period due to patent protections until 2030.
Key Factors Influencing Future Price Trends
- Reimbursement policies: CMS and private payers may impose stricter cost-effectiveness thresholds.
- Market penetration: Higher utilization could lead to tiered pricing models.
- Competition: Introduction of new CGRP inhibitors or biosimilars may exert downward pressure.
- Regulatory developments: Expansion into additional indications could increase demand and stabilize pricing.
Market Entry and Expansion Strategies
- Differentiation through infusion convenience and rapid onset.
- Expansion into primary care with educational initiatives.
- Partnership with payers to secure formulary access and coverage.
Summary
NDC 70710-1111 corresponds to Eptinezumab, which holds a significant position in migraine prophylaxis. Its current price is comparable to, but slightly higher than, subcutaneous competitors, justified by its IV delivery schedule. Future price trajectories will be heavily influenced by market competition, reimbursement policies, and broader adoption.
Key Takeaways
- Eptinezumab's current annual cost is approximately $3,400, with potential for slight reductions through discounts and negotiations.
- The therapeutic niche for IV CGRP inhibitors is expanding, but price competition from subcutaneous options remains intense.
- Market growth is driven by increased migraine prevalence and expanded insurance coverage.
- Longer-term price stability depends on market penetration, regulatory moves, and potential biosimilar entries.
- Strategic focus on differentiation and payer engagement can influence pricing and access.
FAQs
1. What factors affect the pricing of Eptinezumab?
Pricing is influenced by manufacturing costs, reimbursement negotiations, market competition, and formulary positioning.
2. How does Eptinezumab's price compare to other migraine preventives?
It is more expensive per dose than subcutaneous CGRP inhibitors but may have favorable real-world adherence due to quarterly infusions.
3. What is the expected impact of biosimilars on Eptinezumab's price?
Biosimilar entry could lead to significant price reductions, but patent expiration is anticipated around 2030.
4. Are there any notable discounts or rebates for Eptinezumab?
While specific data is proprietary, discounts are common in pharmaceutical markets to secure formulary placement.
5. Could market shifts change the competitive landscape for Eptinezumab?
Yes, new therapeutic innovations, oral CGRP antagonists, or improvements in delivery methods could impact market share and pricing strategies.
References
[1] IQVIA. (2022). Global migraine therapeutics market analysis.
